



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd Dros Dro/ Interim Chair: **Emma Woollett**  
Prif Weithredwr/Chief Executive: **Tracy Myhill**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 3<sup>rd</sup> April 2020  
Ein Cyf / Our Ref: 20-C-023

☎ 01639 648363

✉ FOIA.Requests@wales.nhs.uk

[REDACTED]  
[REDACTED]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 18<sup>th</sup> March 2020. Your request sought information relating to ovarian cancer.

Please note these figures are for the period 01.07.19-31.12.19.

**1. How many patients have been diagnosed over the last 6 months with epithelial ovarian, fallopian tube or primary peritoneal cancer?**

Fallopian Tube Cancer	16
Ovarian Cancer	80
Peritoneal cancer	10

Please note we no longer use codes for Morphology, so cannot provide figures for epithelial ovarian cancer. However, we have provided figures for ovarian cancer. Some patients have more than one diagnosis of the above, so they have been counted more than once.

**a. If none, do you refer ovarian cancer patients to another trust, if so which one?**

Not applicable

**2. Of the ovarian patients, how many have been tested for BRCA mutation? If unknown please state unknown and move to Question 4**

Please note that all patients diagnosed with high grade serous histology (Fallopian tube, ovary, primary peritoneal cancer) in Wales are offered BRCA testing.



**Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR**

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

However in terms of the actual numbers recorded this would not be held centrally. To obtain this information would involve a manual trawl and search of patient records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

**3. Of the ovarian patient BRCA mutation tests how many tested positive?**

Please see question 2

**4. Of the ovarian patients diagnosed over the last 6 months, how many have been treated with the below:**

**Paclitaxel in combination with a platinum-based compound**

**Platinum-based therapy alone (cisplatin or carboplatin)**

**Bevacizumab in combination with paclitaxel and carboplatin**

**Olaparib**

**Niraparib**

**Rucaparib**

**Pegylated liposomal doxorubicin hydrochloride (PLDH) as monotherapy or in combination with a platinum-based compound**

To obtain this information would involve a manual trawl and search of patient records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

**5. Of those who were positive for a BRCA mutation, how many received Olaparib for 1st line maintenance?**

As of 1<sup>st</sup> April 2020, there are currently 6 BRCA positive patients on our prescribing log for Olaparib as first line maintenance.

**6. Of those who were positive for a BRCA mutation, how many received Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance?**

This information is not held centrally. Not all BRCA positive patients are candidates for Bevacizumab. To obtain this information would involve a manual trawl and search of patient records to differentiate which were eligible for Bevacizumab and then the decision made on their treatment, which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.



I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

